Skip to Content

CDC: One-Year Survival 96.1 Percent for Male Breast Cancer

TUESDAY, Oct. 20, 2020 -- For men with a diagnosis of breast cancer during 2007 to 2016, the one- and five-year survival rates were 96.1 and 84.7 percent, respectively, according to research published in the Oct. 16 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Taylor D. Ellington, M.P.H., from the CDC in Atlanta, and colleagues examined relative survival of men with breast cancer diagnosed during 2007 to 2016 by race/ethnicity, age group, stage at diagnosis, and U.S. Census region using data from the National Program of Cancer Registries.

The researchers found one- and five-year survival rates of 96.1 and 84.7 percent, respectively, for men who received a diagnosis of breast cancer during 2007 to 2016. Relative survival varied most by stage at diagnosis among the characteristics examined, with five-year relative survival of 98.7 versus 25.9 percent for cancers diagnosed at localized versus distant stage.

"Using high-quality cancer surveillance to evaluate relative survival among males with breast cancer might help guide health care decisions regarding breast cancer testing and treatment among males and establishing programs to support men at high risk for breast cancer and male breast cancer survivors," the authors write.

Abstract/Full Text

© 2020 HealthDay. All rights reserved.

Posted: October 2020

Read this next

Social Needs Linked to Lower HRQOL for Black Cancer Survivors

MONDAY, Nov. 23, 2020 -- Social needs are associated with lower health-related quality of life (HRQOL) among African American cancer survivors, according to a study published...

Positive BRCA Test Results Down From 2008 to 2018

FRIDAY, Nov. 13, 2020 -- The rate of positive BRCA test results decreased over time from 2008 to 2018, according to a study published online Nov. 5 in JAMA Network Open. Fangjian...

DBT + Synthetic Mammography Better at Repeat Screening

THURSDAY, Nov. 12, 2020 -- At repeat screening, digital breast tomosynthesis plus synthetic mammography (DBT+SM) identifies more cancers than full-field digital mammography...